Registration of financial instruments
20.01.2022 13:24:29 (local time)
With reference to an application submitted under Art. 25 (1) of Part III - Listing Rules and on the grounds of Art. 32 (3) thereof, the BSE Director of Trading has ordered the admission to trading on the Exchange Traded Products Segment of the BSE Main Market of the following issue of warrants:
- Issuer: Sopharma AD-Sofia
- ISIN of the issue: BG9200001212
- BSE code assigned to the issue: SFAW
- CFI code of the issue: RWSTBE
- Type of instrument: Dematerialised, registered and freely transferable warrants
- Amount of the issue: 44,925,943 warrants at the issue price per warrant of BGN 0.28, entitling their holders to exercise within three (3) years the warrants by subscribing to the respective number of shares of the underlying asset, which Sopharma AD is going to issue at a future capital increase
- The underlying asset of the warrants is a future issue of common, registered and dematerialised shares, granting their holders the right to vote at the General Meeting of Shareholders of the issuer, Sopharma AD, having the issue price of BGN 4.13 per share fixed at the moment of warrant subscription as well as a conversion warrant to share ratio of 1:1.
- Issuance currency: BGN
- Currency of trading: BGN
- Start of trading: 25 January 2022 (Tuesday)
- Final date of trading: 09 January 2025
- Segment MIC: ZBUL
- Trading lot: One lot = 1 /one/ warrant
- Minimum tick size: 0.001
- The indicative reference price set for the first trading session: BGN 0.28
INFORMATION ON THE ISSUER:
- Name in the Latin alphabet: Sopharma AD-Sofia
- Seat of business: Sofia, 16 Iliensko shose St.
- UIC: 831902088
- LEI code: 097900BGGW0000048796
- Correspondence address: Sofia, 5 Lachezar Stanchev St.
- Tel.: +359 2 813 45 56
- E-mail: ir@sopharma.bg
- Website: www.sopharma.bg
- Representative: Ognyan Donev
- Investor Relations Director: Pelagia Viyacheva (+359 2 813 43 19, pelagia@sopharma.bg)
- Information disclosure media: www.x3news.com, www.investor.bg
- Scope of business activity: Manufacture of medicines and chemical-pharmaceuticals, trade in the country and abroad, research in the field of phytochemistry, chemistry and pharmacy
Attachments
Original Link
Original Document
Permalink
Disclaimer
Sopharma AD published this content on 20 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 January 2022 15:10:05 UTC.
Sopharma AD, formerly Sopharma AD Sofia, is a Bulgaria-based company engaged in the generic pharmaceutical industry. The Company specializes in the production and trade of medical substances and finished drug forms, as well as research and development in the field of medical products. Through the ampoule plant, tablet plant and the plant in Vrabevo it produces medicines, such as analgesics, antipyretics, cardiovascular medicines as well as drugs for respiratory disease treatment, among others. The Company offers its products under the brand Tribestan, Nivalin and Tabex, among others. In addition, it specializes in the gamma-sterilization of medical materials. It is the parent company of Sopharma Group and operates domestically and abroad in such countries as Russian Federation, Poland, Ukraine, Serbia, the United States and the United Kingdom, among others.
SOPHARMA AD 
